Company news

Alnylam Pharmaceuticals, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Roche and Alnylam advance zilebesiran into global phase III cardiovascular outcomes trial for people with uncontrolled hypertension

August 30, 2025

Genentech and Alnylam Advance Zilebesiran Into Global Phase III Cardiovascular Outcomes Trial for People With Uncontrolled Hypertension

August 29, 2025

Alnylam to Advance Zilebesiran into Global Phase 3 Cardiovascular Outcomes Trial

August 29, 2025

Alnylam to Webcast Presentations at Upcoming September Investor Conferences

August 26, 2025

Scenic Enters License and Research Agreement with Alnylam

August 26, 2025

Alnylam to Present Progress in Transforming the Treatment of Cardiovascular Disease with RNAi Therapeutics at European Society of Cardiology Congress 2025

August 10, 2025

Alnylam to Webcast Presentation at Canaccord Genuity 45th Annual Growth Conference

August 4, 2025

Alnylam Pharmaceuticals Reports Second Quarter 2025 Financial Results and Highlights Recent Period Progress

July 30, 2025

Alnylam to Webcast Conference Call Discussing Second Quarter 2025 Financial Results

July 16, 2025

OXLUMO® (lumasiran injection) Now Reimbursed in Canada For the Treatment of Primary Hyperoxaluria Type 1 (PH1) in Pediatric and Adult Patients

July 2, 2025

Alnylam Announces Promotion of Pushkal Garg to Chief Research and Development Officer

June 17, 2025

Alnylam Receives European Commission Approval for AMVUTTRA® (vutrisiran) for the Treatment of ATTR Amyloidosis with Cardiomyopathy

June 8, 2025

Alnylam to Webcast Presentation at Goldman Sachs 46th Annual Global Healthcare Conference

May 27, 2025

Alnylam Issues 2024 Corporate Responsibility Report

May 19, 2025

AMVUTTRA® (vutrisiran) Significantly Reduces Mortality and a Range of Important Cardiovascular Events in Patients with ATTR Amyloidosis with Cardiomyopathy: Additional Data from HELIOS-B

May 16, 2025

Alnylam to Share Progress Across its Transthyretin Amyloidosis Franchise Including Additional Analyses of the HELIOS-B Phase 3 Study Results at Heart Failure 2025 Congress

May 11, 2025

Alnylam to Webcast Presentation at BofA Securities 2025 Health Care Conference

May 4, 2025

Alnylam Pharmaceuticals Reports First Quarter 2025 Financial Results and Highlights Recent Period Progress

April 30, 2025

Alnylam Receives Positive CHMP Opinion for Vutrisiran for the Treatment of ATTR Amyloidosis with Cardiomyopathy

April 27, 2025

Alnylam to Webcast Conference Call Discussing First Quarter 2025 Financial Results

April 16, 2025

Alnylam to Webcast Presentation at Needham 24th Annual Virtual Healthcare Conference

March 31, 2025

Alnylam Presents New Data from the HELIOS-B Phase 3 Study of Vutrisiran in Patients with ATTR Amyloidosis with Cardiomyopathy (ATTR-CM) at the American College of Cardiology’s Annual Scientific Session 2025

March 28, 2025

FDA Approves Qfitlia™ (fitusiran), the First siRNA (RNAi Therapeutic) for the Treatment of Hemophilia A or B

March 27, 2025

Alnylam Announces FDA Approval of AMVUTTRA® (vutrisiran), the First RNAi Therapeutic to Reduce Cardiovascular Death, Hospitalizations and Urgent Heart Failure Visits in Adults with ATTR Amyloidosis with Cardiomyopathy (ATTR-CM)

March 19, 2025

Alnylam to Webcast Presentation at Stifel 2025 Virtual CNS Forum

March 10, 2025

Alnylam Announces Retirement of Longtime Board Member, Dr. Phillip A. Sharp, Company Co-Founder and Industry Luminary

March 4, 2025

Alnylam Highlights Significant Pipeline Progress and Platform Innovation at R&D Day

February 24, 2025

Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Period Progress

February 12, 2025

Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2024 Financial Results

January 29, 2025

Alnylam Announces Preliminary* Fourth Quarter and Full Year 2024 Global Net Product Revenues and Provides 2025 Combined Net Product Revenue Guidance and Pipeline Goals

January 11, 2025

Alnylam to Webcast Presentation at 43rd Annual J.P. Morgan Healthcare Conference

January 5, 2025

Alnylam to Webcast Presentation at Piper Sandler 36th Annual Healthcare Conference

November 26, 2024

Alnylam Announces U.S. Food and Drug Administration Acceptance of Supplemental New Drug Application for Vutrisiran for the Treatment of ATTR Amyloidosis with Cardiomyopathy

November 24, 2024

Alnylam Announces Interim Phase 1 Data of Nucresiran (ALN-TTRsc04) Showing Rapid Knockdown of TTR that is Sustained at Six Months Following a Single Dose

November 16, 2024

Alnylam Pharmaceuticals Reports Third Quarter 2024 Financial Results and Highlights Recent Period Activity

October 30, 2024

Alnylam to Showcase Latest Data from TTR Franchise and Hypertension Program at American Heart Association Scientific Sessions 2024

October 29, 2024

Alnylam to Webcast Conference Call Discussing Third Quarter 2024 Financial Results

October 16, 2024

Alnylam Submits Regulatory Application to the European Medicines Agency for Vutrisiran for the Treatment of ATTR Amyloidosis with Cardiomyopathy

October 15, 2024

Alnylam Submits Supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration for Vutrisiran for the Treatment of Transthyretin Amyloidosis with Cardiomyopathy

October 8, 2024

Alnylam Highlights New Data From HELIOS-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis With Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024

September 28, 2024

Alnylam to Webcast TTR Investor Day

September 25, 2024

Alnylam Presents Detailed Results from the Positive HELIOS-B Phase 3 Study of Vutrisiran▼ in Patients with ATTR Amyloidosis with Cardiomyopathy at the European Society of Cardiology Congress

August 29, 2024

Alnylam to Present Detailed Results from the HELIOS-B Phase 3 Study of Vutrisiran▼ in Patients with ATTR Amyloidosis with Cardiomyopathy at the European Society of Cardiology Congress 2024

August 6, 2024

Alnylam Pharmaceuticals Reports Second Quarter 2024 Financial Results and Highlights Recent Period Activity

July 31, 2024

Alnylam to Webcast Conference Call Discussing Second Quarter 2024 Financial Results

July 17, 2024

Alnylam Reports Positive Topline Results from HELIOS-B Phase 3 Study of Vutrisiran, Achieving Statistical Significance on Primary and All Secondary Endpoints in Both Overall and Monotherapy Populations

June 23, 2024

Alnylam Issues 2023 Corporate Responsibility Report

May 6, 2024

Alnylam Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Period Activity

May 1, 2024

Medison Pharma and Alnylam Pharmaceuticals Announce Expansion of their Multi-Regional Partnership in Europe and Israel to Commercialize RNAi Therapeutics in additional LATAM and APAC markets including Australia

April 29, 2024

Alnylam to Webcast Conference Call Discussing First Quarter 2024 Financial Results

April 17, 2024

← Newer news releases · Older news releases →

Calls

The 5 newest of 25 calls. Every call is listed under its year.

Decks

The 5 newest of 89 decks. Every deck is listed under its year.